Resveratrol suppresses lung cancer by targeting cancer stem-like cells and regulating tumor microenvironment

Increasing evidence indicate that cancer stem cells (CSCs) are the key driver of tumor initiation and recurrence. The cellular and soluble components of the tumor microenvironment (TME) impact on cancer initiation and progression, such as cytokines and chemokines. Thus, targeting CSCs and TME is a novel anti-cancer approach. Resveratrol (RES), a bioactive phytochemical extracted from various plants, exhibits tumor-suppressing activities in lung cancer, yet the mechanism remains poorly understood. Our data showed that the expression level of IL-6 was positively correlated with the presence of lung cancer stem-like cells (LCSCs) in human lung cancer tissues. In vitro results showed that IL-6 was highly elevated in lung cancer sphere-forming cells and could enhance the stemness of LCSCs, including tumor sphere formation ability, the percentage of CD133 positive cells, and the expression of LCSC specific markers (CD133, ALDH1A1 and Nanog). Simultaneously, our results confirmed that RES effectively inhibited LCSC properties, downregulated Wnt/beta-catenin signaling and reduced IL-6 level in vitro and in vivo . Furthermore, we found RES treatment attenuated the activation of Wnt/beta-catenin signaling by LiCl (GSK3 beta agonist). IL-6-promoted LCSC properties and Wnt/beta-catenin signaling was also reversed by RES. Taken together, these data illustrated that RES inhibited lung cancer by targeting LCSCs and IL-6 in TME. The novel findings from this study provided evidence that RES exhibited multi-target effects on suppression of lung cancer and could be a novel potent cancer-preventive compound.(c) 2022 Elsevier Inc. All rights reserved.

Automated summary

Increasing evidence suggests that cancer stem cells (CSCs) play a crucial role in tumor initiation and recurrence. Targeting CSCs and the tumor microenvironment (TME) is a novel anti-cancer approach. Resveratrol (RES) inhibits lung cancer by targeting lung cancer stem-like cells (LCSCs) and IL-6 in the TME.